

1 **Development of a non-infectious control for viral hemorrhagic fever PCR assays**

2

3 Matthew A Knox*¹, Collette Bromhead², David TS Hayman¹

4

5 1. Massey University, School of Veterinary Science, Palmerston North, Manawatu-

6 Wanganui, New Zealand

7 2. Massey University, School of Health Sciences, Wellington, New Zealand

8

9 * corresponding author M.Knox@massey.ac.nz

10

11 **Abstract**

12 Assay validation is an essential component of disease surveillance but can be problematic in
13 low resource settings where access to positive control material is limited and a safety risk for
14 handlers. Here we describe techniques for validating the PCR based detection of *Crimean-*
15 *Congo hemorrhagic fever orthonairovirus*, Ebola virus, Lassa virus, Marburg virus and *Rift*
16 *Valley Fever phlebovirus*. We designed non-infectious synthetic DNA oligonucleotide
17 sequences incorporating primer binding sites suitable for multiple assays, and a T7 promotor
18 site which was used to transcribe the sequence. Transcribed RNA was used as template in a
19 dilution series, extracted and amplified with RT-PCR and RT-qPCR to demonstrate
20 successful recovery and determine limits of detection in a range of laboratory settings. Our
21 results are adaptable to any assay requiring validation of nucleic acid extraction and/or
22 amplification, particularly where sourcing reliable, safe material for positive controls is
23 infeasible.

24

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **Author Summary**

27

28 The majority of zoonoses originate in wildlife and tend to emerge from biodiverse regions in

29 low to middle income countries, frequently among deprived populations of at-risk people

30 with a lack of access to diagnostic capacity or surveillance. Diseases such as Crimean-Congo

31 Hemorrhagic Fever, Rift Valley Fever, Ebola Virus Disease, Marburg Virus Disease and

32 Lassa Fever are viral hemorrhagic fevers (VHFs) and among the most neglected and serious

33 threats to global public health. This threat is partly due to the severity of disease caused by

34 these pathogens, but also because their geographical distribution is close to human

35 populations with often limited access to medical or diagnostic laboratory services. In our

36 study we describe and validate techniques for PCR based detection of five VHF viruses using

37 a synthetic, multi-target non-infectious positive control. Our work has applications in assay

38 design and optimization, particularly where access to source material is problematic or

39 requires high level biosafety containment, as is the case with VHF viruses. This approach can

40 help learners train in techniques used in nucleic acid extraction, amplification, and

41 sequencing of VHF viruses, but can be used for any targets, with potential for multiplexing

42 from a single positive control.

43

44

45 **Introduction**

46 Medical advances including to healthcare access and sanitation have reduced infectious
47 disease mortality and morbidity globally. However, infectious diseases remain a significant
48 burden to many of the most deprived people in the world, and emerging infectious diseases
49 (EIDs) are serious public health threats, as evidenced by the emergence of SARS-CoV-2 and
50 COVID-19 pandemic in 2019 (1). Most EIDs are zoonotic in origin, meaning they emerge
51 from an animal and cross the species barrier to infect humans. Factors that lead to EID
52 emergence include socioeconomic factors, land use change, and urban population growth (2-
53 5). The majority of zoonoses (e.g. ~72% (3)) originate in wildlife and because of these
54 processes they tend to emerge from biodiverse regions in low to middle income countries
55 (LMICs) and frequently among deprived populations of at-risk people with a lack of access to
56 diagnostic capacity or surveillance. The recent global emergence of monkeypox virus
57 highlights the diagnostic issue further (6); the virus that causes Mpox (monkeypox), an
58 endemic zoonosis in West and Central Africa, must have emerged locally, possibly in
59 Nigeria, and gone undetected until it was detected in Europe (6).

60 Diseases such as Crimean-Congo Hemorrhagic Fever (CCHF), Rift Valley Fever (RVF),
61 Ebola Virus Disease (EVD), Marburg Virus Disease (MVD) and Lassa Fever (LF) are viral
62 hemorrhagic fevers (VHFs) and among the most neglected and serious threats to global
63 public health. This is in part due to the severity of disease caused by these pathogens, but also
64 because their geographical distribution is close to human populations with often limited
65 access to medical or diagnostic laboratory services. The large West African EVD outbreak
66 was likely able to establish during the months after the first case because early cases were not
67 detected in areas poorly served by diagnostic services (7). There is therefore an urgent need
68 to develop tools for surveillance and diagnosis for both people and wildlife hosts for the
69 VHFs (8).

70 Numerous diagnostic assays exist for the viral agents of these VHF (9-14). However, there
71 are difficulties in training personnel, particularly for VHF and pathogens that are both rare
72 and highly pathogenic (15-17). Developments in synthesizing nucleic acids, however, allow
73 the synthesis of non-infectious control material for safe handling, including in low resource
74 settings (18, 19). Here, we designed synthetic DNA oligonucleotide sequences incorporating
75 primer binding sites suitable for five VHF (CCHF, RVF, EVD, MVD, LF) causing viruses
76 including a T7 promotor site to transcribe the sequence to enable RNA synthesis and provide
77 positive control material for all laboratory steps from nucleic acid extraction to detection. We
78 tested the sensitivity of extraction using both RT-PCR and RT-qPCR. In addition, since
79 access to refrigeration and cold storage is often not possible in field settings, we assess the
80 stability of reagents for amplification after storage at ambient temperature over a one-week
81 time course.

82

83 **Methods**

84 **VHF Control Vector**

85 A 1,000 bp DNA fragment was designed by generating random nucleotide sequence and
86 embedding previously published primer binding sites (9-14) within the sequence at positions
87 designed to amplify the target amplicon size for each assay. The fragment contained primer
88 binding positions for the amplification of five negative strand RNA viral pathogens,
89 comprising three viruses from the order Bunyvirales: *Crimean-Congo hemorrhagic fever*
90 *orthonairovirus* (CCHFV, family Nairoviridae), Lassa virus (LV, *Lassa mammarenavirus*,
91 family Arenaviridae), and *Rift Valley fever phlebovirus* (RVFV, family *Phenuiviridae*), and
92 two viruses from the order Mononegavirales: Ebola virus (EV, *Zaire ebolavirus*, family
93 Filoviridae) and Marburg virus (MV, *Marburg marburgvirus*, family Filoviridae) (Figure 1,
94 Table 1).

95



96

97

98 **Figure 1.** Viral hemorrhagic fever synthetic insert with primer sequence locations. See text

99 and Table 1 for details.

100 **Table 1.** Primers and probes for RT-PCR and RT-qPCR

101


Virus*	Forward primer (5'-3')	Reverse primer (5'-3')	Size (bp)	Reference
CCHFV	TCTCAAAGAAACACGTGCC	CCTTTTTGAACTCTTCAAACC	122	Atkinson et al., 2012
EV	TGGGCTGAAAAYTGCTACAA TC	CTTTGTGMACATASCGGCAC	111	Gibb et al., 2001
LV (long)	ACCGGGGATCCTAGGCATTT	ATGACMATGCCCTKTCCTGC ACAAAGAAC	580	Olschläger et al., 2010
LV (Short RT- qPCR)	AGCCTGATCCAGATGCCAC ACATCTAG	TGCTGTTGGAGCGGCTGATGGT CTCAG	197	He et al., 2009
MV	GGTCAAACACTAGATTCTCAGG ACTTC	GTCACCCCTGAATCAGTTTTTTT	80	Huang et al 2012
RVFV	ATGATGACATT GAAGGGA	ATGCTGGGAAGTGATGAG	298	Garcia et al., 2001
β-globin internal control	AGAATCCAGATGCTCAAGGC	AGGTCCTTTGTTCCCTAAGT	72	C. Bromhead; this study

102 *CCHFV: *Crimean-Congo hemorrhagic fever orthonairovirus*; EV: Ebola virus; LV: Lassa virus; MV:

103 Marburg virus, and: RVFV: *Rift Valley Fever phlebovirus*.

104

105 The synthesised product was manufactured by GeneScript and cloned using pET-20b(+)
106 vector, which includes a T7 promoter site (Figure 2). The resulting lyophilized plasmid DNA
107 was reconstituted in 20 μ L sterile water. RNA copies of the fragment were generated from
108 plasmid DNA using the MAXIscript T7 In Vitro Transcription kit (Ambion) following the
109 manufacturer's instructions. Synthesized RNA was then quantified using Qubit™ RNA HS
110 (High Sensitivity) Assay Kit and stored at -80°C until further analyses. We estimated the
111 copy number based on the calculation which can be found at
112 <http://www.scienceprimer.com/copy-number-calculator-for-realtime-pcr>.
113



114
115 **Figure 2.** pET-20b(+) vector including insert, which is the sequence in Figure 1.

116

117 **RNA extraction and 1-step RT-PCR**

118 To simulate the biological sample processing steps, the synthetic VHF control RNA (550 -
119 5.5×10^{11} copies) was added to 1 mL sterile PBS and then passed through a sterile 0.45 μm
120 filter (Macherey-Nagel GmbH & Co. KG, Düren, Germany). We used 200 μL of filtrate as
121 the input material for nucleic acid extraction using the High Pure Viral Nucleic Acid kit
122 (Roche, New Zealand) according to the manufacturer's procedure. Extracted RNA was
123 amplified by 1 step RT-PCR using each of the five VHF primer sets (Table 1) and assay-
124 specific cycling protocols (Table 2). Each 20 μL reaction consisted of 0.25 μM each primer,
125 1 pg-1 μg of template RNA (VHF Control Vector, GeneScript USA), 1 x PCR buffer and 0.5
126 μL SuperScript™ III RT/Platinum™ Taq High Fidelity Enzyme Mix (Invitrogen). RT-PCR
127 products were separated by agarose gel electrophoresis and visualised under UV light where
128 bands of the expected size were identified and excised. DNA was eluted in 50 μL buffer (10
129 mM Tris, pH 8.0) for 12–24 hours at 4°C and then sent for bi-directional Sanger sequencing
130 to the Massey Genome Service (Massey University, Palmerston North, New Zealand).

131

132 **Table 2.** Cycling conditions for 1-step RT-PCR assays

Virus*	Amplification**			Cycles
CCHFV	95°C 10 s	55°C 30 s	68°C 30 s	45
EV	94°C 15 s	60°C 30 s	68°C 30 s	40
LV (Long)	95°C 20 s	55°C 20 s	68°C 60 s	45
MV	94°C 15 s	60°C 30 s	68°C 30 s	45
RVFV	95°C 15 s	55°C 30 s	68°C 30 s	45

133 *CCHFV: *Crimean-Congo hemorrhagic fever orthonairovirus*; EV: Ebola virus; LV: Lassa
134 virus; MV: Marburg virus, and: RVFV: *Rift Valley Fever phlebovirus*. **Note that all 1-step
135 RT-PCR assays started with a cDNA synthesis step at 55°C for 30 min followed by an initial
136 denaturation at 95°C for 2 min.

137

138 To test the sensitivity of the nucleic acid extraction and 1-step RT-PCR assays, we conducted
139 a dilution series with the synthesized RNA. Dilutions for extraction were prepared in PCR

140 grade water and ranged from 31.2 to 3.12×10^{-8} ng (copy numbers 5.5×10^{11} to 550) and
141 followed the same biological sample processing steps as above.

142 **RT-qPCR assay and reagent stability experiments**

143 All RT-qPCR assays used Ultraplex 1-Step ToughMix (Quantabio) and Eva®Green 20x
144 (Biotium, both from DNature NZ Ltd) on a Roche LightCycler-96 instrument. We included
145 two additional primer sets for RT-qPCR assays: a shorter Lassa virus amplicon (14) and a
146 beta-globin internal cellularity control (β -globin) which we found could be duplexed with
147 each VHF assay. Cycling conditions were optimised by testing annealing temperature
148 gradients from 55°C to 60°C in duplicate for all seven assays under the following
149 thermocycler conditions: 50°C for 10 mins, 95°C for 3 mins, 55 cycles of 95°C for 5 s, 55-
150 60°C for 15 s, 72°C for 30 s, with fluorescence acquired during the extension step
151 (excitation/emission Eva green = 488/530 nm). See Table 3 for optimal run conditions for
152 each VHF. Primer concentrations were optimised by titration from 0.2 to 0.6 μ M in 0.05 μ M
153 increments using a dilution series from 5000 copies/ μ L to 0.5 copies/ μ L of the synthetic
154 control extracted as for test samples (High Pure Viral kit, Roche New Zealand). The dilution
155 series was used to determine the limit of detection of each assay (see results, Table 3).
156 Optimal reagent conditions for each VHF+ β -globin RT-qPCR assay, in a 10 μ L reaction,
157 consisted of 1 x Toughmix 1-step buffer, 1 x Eva green dye, 0.45 μ M each primer (VHF + β -
158 globin), synthetic RNA control (50-5000 copies/ μ L) and RNase-free water.
159 To assess the performance of our assays under potential field conditions where refrigeration
160 may not be available, we tested the performance of RT-qPCR reagents Ultraplex 1-Step
161 ToughMix and Eva®Green 20x stored at room temperature (12-28°C) for up to 1 week
162 before use. Duplicate RT-qPCR tests for each VHF were performed at each of three
163 timepoints (24 hours, 72 hours and 168 hours, 7 days) using the room temperature reagents.

164 Synthesised RNA from the VHF Control Vector was used as the template at a concentration
165 of 1,600-2,500 copies/ μ L.

166

167 **Results**

168 **Dilution series RNA extraction and RT-PCR**

169 RT-PCR performance varied among the assays (Supplementary Table 1, Supplementary
170 Figure 1). The results of a dilution series of synthetic control from 5.5E+11 to 552 copies
171 showed all five assays could detect to a limit of ~5.5 million copies/ μ L by gel
172 electrophoresis, while the LV and MV could reliably detect 5.5E+4 and gave visible weak
173 bands at ~550 copies/ μ L. Sequencing of excised amplified products confirmed that recovered
174 DNA matched target amplicons (data not shown).

175 **VHF RT-qPCR assay and time course experiment**

176 The RT-qPCR assays underwent optimisation for annealing temperatures, primer
177 concentrations and high-resolution melt (HRM) analysis. The results for these parameters as
178 well as the limits of detection for each RT-qPCR assay is shown in Table 3 and Figure 3.


179

180 **Table 3.** RT-qPCR VHF virus assay optimal experimental conditions and limits of detection.

Target*	Optimal annealing temperatures ($^{\circ}$ C)	TM of melting peaks ($^{\circ}$ C)	Limit of detection (copies/ μ L)
EV	55-61	82.5	50
RVFV	55-56	82.5	50
CCHFV	55-62	83	50
MV	55-61	78	50
LV-long	55-65	77	500
LV-short	55-58	81	50
β -globin	55-60	81	10

181 *CCHFV: EV: Ebola virus; RVFV: *Rift Valley Fever phlebovirus*; *Crimean-Congo*

182 *hemorrhagic fever orthonairovirus*; MV: Marburg virus, and: LV: Lassa virus.



184 **Figure 3.** High resolution melting peaks for EV and CCHFV (red), RVFV (turquoise), MV
185 (yellow) Short LV and β -globin (81°C purple), Long LV (77°C purple). Colours are grouped
186 by melting temperature (°C).


187
188 All assays could reliably detect 50 copies per μL except for the long LV assay which could
189 only detect down to 500 copies/ μL reliably. The decreased efficiency of this assay indicated
190 it was not suitable for qPCR conversion. No change in primer concentration (0.45 mM) was
191 required for combining a VHF assay with the β -globin internal control (data not shown) and a
192 standard annealing temperature of 56°C was found to suit all assays.

193 We tested the performance of our VHF assays using RT-qPCR reagents stored at room
194 temperature (12-28°C), in the dark, for up to 1 week. Duplicate RT-qPCR tests for each VHF
195 were performed at each of three timepoints (24 hours, 72 hours and 7 days) using the
196 synthetic RNA control at a concentration of 1,600-2,500 copies/ μL .

197 The average Cq values at 24 hours, 72 hours and 1 week all rose compared to time zero
198 (using ideal frozen reagents). The VHF virus RT-qPCR's biggest change was between 72
199 hours and 1 week for each VHF virus assay (Figure 4). The average Cq values were highest
200 for the LV assays, particularly the Long LV, indicating it was the most sensitive to reduced
201 efficiency reagents. By contrast, the MV assay maintained a low Cq across all three time
202 points. After 1 week, assay sensitivity for detecting 1000 copies/ μL is significantly

203 compromised. Therefore 3 days (72 hours) at room temperature is the maximum
204 recommended storage time for Ultraplex 1-Step ToughMix (Quantabio) and Eva®Green 20x
205 (Biotium) for this testing purpose (See Supplementary Table 2 for the raw Cq data).

206



207

208 **Figure 4.** Room temperature stability of ToughMix and Eva Green for VHF virus RT-qPCR
209 assays.

210

211 Discussion

212 We have developed six assays for the most commonly occurring viral causes of VHF's using
213 both RT-PCR and RT-qPCR, incorporating an internal control for the latter, with the
214 possibility of multiplexing and using reagents stored at room temperature for up to 72 hours.
215 Our results demonstrate the applicability of synthetically designed nucleic acids for use as
216 molecular diagnostic assay controls in both RT-PCR and RT-qPCR methods. This work has
217 applications for assay design and optimization, particularly where access to source material is
218 problematic or requires high level biosafety containment, as is the case with VHF viruses.

219 This approach can help learners to train in techniques used in nucleic acid extraction,
220 amplification, and sequencing of VHF viruses, however, as well as providing ongoing
221 validation for the VHF viral assays we present, this approach can be used for any targets,
222 with potential for multiplexing from a single positive control.

223 Recent technological advances have greatly improved virus detection and diagnosis without
224 the need for multi-step RNA purification (20). New generation RT-qPCR reagents are more
225 robust to temperature storage above -20°C. These tests provide rapid, inexpensive, and
226 robust diagnoses where laboratory infrastructure is not available, and may replace current
227 technologies (i.e., RT-PCR assays) in some settings. However, there is an urgent need to
228 develop in-country tools for surveillance and diagnosis for both people and wildlife hosts for
229 the VHFs (8). Since our workflow requires only standard equipment, currently present in
230 most molecular biology labs it has applications for the design and validation of tests used in
231 surveillance of VHFs in countries where such work is most needed and for the time being
232 RT-PCR is likely to remain the most common method for many diagnostic laboratories.
233 Therefore, safe approaches to generate control material and to train staff are needed and our
234 work provides further evidence for the applicability of synthetic nucleic acids for use as assay
235 controls.

236 **Acknowledgements**

237 This work was supported by funds from the World Organisation for Animal Health (Grant
238 3000034275; OIE Laboratory (or Collaborating Centre) Twinning Project: Enhancing
239 capacity for early detection of viral haemorrhagic fevers in Liberia through epidemiological
240 and laboratory training), Royal Society Te Apārangi Rutherford Discovery Fellowship (RDF-
241 MAU1701) and the Percival Carmine Chair in Epidemiology and Public Health (DTSH). We
242 wish to acknowledge the valuable contributions of WOA staff, particularly Sophie Muset
243 and Mariana Marrana, and the Central Veterinary Laboratory team in Liberia.

244 Citations

- 245 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from
246 patients with pneumonia in China, 2019. *New England journal of medicine*. 2020.
- 247 2. Jones BA, Grace D, Kock R, Alonso S, Rushton J, Said MY, et al. Zoonosis
248 emergence linked to agricultural intensification and environmental change. *Proceedings of*
249 *the National Academy of Sciences*. 2013;110(21):8399-404.
- 250 3. Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, et al. Global
251 trends in emerging infectious diseases. *Nature*. 2008;451(7181):990-3.
- 252 4. Rulli MC, Santini M, Hayman DT, D'Odorico P. The nexus between forest
253 fragmentation in Africa and Ebola virus disease outbreaks. *Scientific reports*. 2017;7:41613.
- 254 5. Stephens PR, Gottdenker N, Schatz AM, Schmidt JP, Drake JM. Characteristics of the
255 100 largest modern zoonotic disease outbreaks. *Philosophical Transactions of the Royal*
256 *Society B: Biological Sciences*. 2021;376(1837):20200535.
- 257 6. Gessain A, Nakoune E, Yazdanpanah Y. Monkeypox. *New England Journal of*
258 *Medicine*. 2022;387(19):1783-93.
- 259 7. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba NF, et al.
260 Emergence of Zaire Ebola virus disease in Guinea. *New England Journal of Medicine*.
261 2014;371(15):1418-25.
- 262 8. Maudling R. How can One Health contribute to pandemic prevention? Looking at
263 Ebola through a One Health lens. *CABI One Health*. 2022(2022):ohcs20220004.
- 264 9. Atkinson B, Chamberlain J, Logue CH, Cook N, Bruce C, Dowall SD, et al.
265 Development of a real-time RT-PCR assay for the detection of Crimean-Congo hemorrhagic
266 fever virus. *Vector Borne Zoonotic Dis*. 2012;12(9):786-93.
- 267 10. Garcia S, Crance JM, Billecocq A, Peinnequin A, Jouan A, Bouloy M, et al.
268 Quantitative real-time PCR detection of Rift Valley fever virus and its application to
269 evaluation of antiviral compounds. *J Clin Microbiol*. 2001;39(12):4456-61.
- 270 11. Gibb TR, Norwood DA, Jr., Woollen N, Henchal EA. Development and evaluation of
271 a fluorogenic 5' nuclease assay to detect and differentiate between Ebola virus subtypes Zaire
272 and Sudan. *J Clin Microbiol*. 2001;39(11):4125-30.
- 273 12. Huang Y, Wei H, Wang Y, Shi Z, Raoul H, Yuan Z. Rapid detection of filoviruses by
274 real-time TaqMan polymerase chain reaction assays. *Virol Sin*. 2012;27(5):273-7.
- 275 13. Olschläger S, Lelke M, Emmerich P, Panning M, Drosten C, Hass M, et al. Improved
276 detection of Lassa virus by reverse transcription-PCR targeting the 5' region of S RNA. *J Clin*
277 *Microbiol*. 2010;48(6):2009-13.
- 278 14. He J, Kraft AJ, Fan J, Van Dyke M, Wang L, Bose ME, et al. Simultaneous Detection
279 of CDC Category "A" DNA and RNA Bioterrorism Agents by Use of Multiplex PCR & RT-
280 PCR Enzyme Hybridization Assays. *Viruses*. 2009;1(3):441-59.
- 281 15. Worsley-Tonks KE, Bender JB, Deem SL, Ferguson AW, Fèvre EM, Martins DJ, et
282 al. Strengthening global health security by improving disease surveillance in remote rural
283 areas of low-income and middle-income countries. *The Lancet Global Health*.
284 2022;10(4):e579-e84.
- 285 16. Molyneux D, Hallaj Z, Keusch GT, McManus DP, Ngowi H, Cleaveland S, et al.
286 Zoonoses and marginalised infectious diseases of poverty: where do we stand? *Parasites &*
287 *vectors*. 2011;4(1):1-6.
- 288 17. Organization WH. WHO consultative meeting high/maximum containment (biosafety
289 level 4) laboratories networking: venue: International Agency on Research on Cancer
290 (IARC), Lyon, France, 13-15 December 2017: meeting report. 2018.

- 291 18. Hayman DT, Banyard AC, Wakeley PR, Harkess G, Marston D, Wood JL, et al. A
292 universal real-time assay for the detection of Lyssaviruses. *Journal of virological methods*.
293 2011;177(1):87-93.
- 294 19. King DP, Reid SM, Hutchings GH, Grierson SS, Wilkinson PJ, Dixon LK, et al.
295 Development of a TaqMan® PCR assay with internal amplification control for the detection
296 of African swine fever virus. *Journal of Virological Methods*. 2003;107(1):53-61.
- 297 20. Pollak NM, Olsson M, Marsh GA, Macdonald J, McMillan D. Evaluation of three
298 rapid low-resource molecular tests for Nipah virus. *Front Microbiol*. 2022;13:1101914.
299

300

301 **CreDit Author Contributions**

302

303 **Matthew A Knox:** Investigation, Methodology, Formal Analysis, Visualization, Writing –
304 Original Draft Preparation.

305

306 **Collette Bromhead:** Investigation, Methodology, Validation, Formal Analysis, Writing –
307 Review & Editing.

308

309 **David TS Hayman:** Conceptualization, Funding Acquisition, Project Administration,
310 Writing – Review & Editing.

311

312